{
    "clinical_study": {
        "@rank": "36970", 
        "arm_group": [
            {
                "arm_group_label": "Unifed Protocol (UP) for Discontinuation", 
                "arm_group_type": "Experimental", 
                "description": "Unified Protocol (UP) for Discontinuation is delivered in 14 weekly individual sessions of 45-60 minutes followed by 3 booster sessions scheduled at two, four and eight weeks thereafter. The UP is a cognitive behavioral treatment that focuses on  increasing emotional awareness and cognitive flexibility, preventing behavioral and emotional avoidance, and situational and interoceptive emotion-focused exposure. Participants will also receive 7 biweekly medication management sessions over 14 weeks with a study psychiatrist to facilitate gradual taper of SRI medication."
            }, 
            {
                "arm_group_label": "Taper and Monitoring (TAP-M)", 
                "arm_group_type": "Active Comparator", 
                "description": "Taper and Monitoring (TAP-M) is delivered in biweekly individual sessions over 14 weeks, with booster sessions at two, four, and eight weeks thereafter.  TAP-M consists of assessment and monitoring.  Participants will also receive 7 biweekly medication management sessions over 14 weeks with a study psychiatrist to facilitate gradual taper of SRI medication."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will address questions of fundamental clinical significance including: (1)\n      whether OCD patients maintained on long term SRIs can be discontinued without symptom\n      exacerbation, (2) whether transdiagnostic cognitive-behavioral treatment will reduce\n      worsening following discontinuation compared to Taper and Monitoring, and (3) whether\n      predictors of successful SRI discontinuation can be identified."
        }, 
        "brief_title": "Assisting Obsessive Compulsive Disorder (OCD) Patients With Discontinuing Long-term Serotonin Reuptake Inhibitors (SRIs)", 
        "condition": "Obsessive Compulsive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Obsessive-Compulsive Disorder", 
                "Compulsive Personality Disorder"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. 18 to 65 years of age\n\n          2. Presence of mild to moderate OCD symptoms as defined by a YBOCS score between 12 and\n             23\n\n          3. Patient's treating clinician agrees that SRI discontinuation is clinically\n             appropriate\n\n          4. Adequate trial of SRI (\u226510 weeks) in the current treatment episode\n\n          5. Maintenance on SRI dose that has not increased due to significant clinical worsening\n             in the two years prior to enrollment\n\n          6. English speaking\n\n        Exclusion Criteria:\n\n          1. Clinically significant suicidality or a suicide attempt within the past year\n\n          2. Presence of any clinical features warranting a higher level of care (partial or\n             inpatient hospitalization)\n\n          3. Current or recent (past 6 months) alcohol or drug dependence or abuse\n\n          4. Current or past psychotic disorder or bipolar disorder\n\n          5. Moderate to severe depression, as indicated by a Hamilton Rating Scale for Depression\n             (HRSD) (17-item) \u2265 14 or recent major depressive episode (past 6 months)\n\n          6. History of psychotic or recurrent depression\n\n          7. History of severe OCD (YBOCS \u2265 28)\n\n          8. Prior adverse experience with SRI discontinuation\n\n          9. Primary compulsive hoarding\n\n         10. Cognitive impairment that would interfere with study participation\n\n         11. Concomitant psychosocial treatment w/ proven efficacy in the treatment of OCD\n\n         12. Previous adequate trial of exposure-based treatment (e.g., history of 12 or more\n             sessions)\n\n         13. Use of non-SRI psychotropic medications for OCD in the 3 months prior to enrollment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02103621", 
            "org_study_id": "1402-002", 
            "secondary_id": [
                "1R21MH100444-01A1", 
                "1402-002"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Unifed Protocol (UP) for Discontinuation", 
                "intervention_name": "Unified Protocol (UP)", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": "Taper and Monitoring (TAP-M)", 
                "intervention_name": "Taper and Monitoring (TAP-M)", 
                "intervention_type": "Behavioral"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Serotonin Uptake Inhibitors"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 1, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Providence", 
                    "country": "United States", 
                    "state": "Rhode Island", 
                    "zip": "02906"
                }, 
                "name": "Butler Hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Discontinuation of Long-term SRIs in Obsessive Compulsive Disorder", 
        "overall_contact": {
            "email": "christina_boisseau@brown.edu", 
            "last_name": "Christina L Boisseau, Ph.D.", 
            "phone": "401-455-6236"
        }, 
        "overall_contact_backup": {
            "email": "steven_rasmussen@brown.edu", 
            "last_name": "Steven A Rasmussen, M.D.", 
            "phone": "401-455-6209"
        }, 
        "overall_official": {
            "affiliation": "Butler Hospital", 
            "last_name": "Christina L Boisseau, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Yale-Brown Obsessive Compulsive Scale (Y-BOCS)", 
            "safety_issue": "Yes", 
            "time_frame": "14 weeks post baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02103621"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Butler Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute of Mental Health (NIMH)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Butler Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}